Orphazyme A/S (NASDAQ:ORPH) saw an upside of 0.76% to close Tuesday at $3.98 after adding $0.03 on the day. The 5-day average trading volume is 917,220 shares of the company’s common stock. It has gained $4.31 in the past week. An average of 726,225 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,043,116.
ORPH’s 1-month performance is -14.96% or -$0.83 on its low of $3.78 reached on 10/08/21. The company’s shares have touched a 52-week low of $3.78 and high of $77.77, with the stock’s rally to the 52-week high happening on 06/10/21. YTD, ORPH has lost -62.91% or -$6.75. However, the current price is down -94.88%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Orphazyme A/S (ORPH) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.ORPH stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 72.71 while the price-to-book (PB) in the most recent quarter is 5.38.
ORPH stock balance sheet for the recent quarter shows that total liabilities totaled 42.35 million, with total debt at $58.59 million
Let’s look briefly at Orphazyme A/S (ORPH) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 37.79% to suggest the stock is trending Neutral, with historical volatility in this time period at 36.97%.
The stock’s 5-day moving average is $3.90, reflecting a -0.25% or -$0.01 change from its current price. ORPH is currently trading -12.91% above its 20-day SMA, -27.77% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -16.21% and -66.83% respectively.
Stochastic %K and %D was 15.61% and 11.31% and the average true range (ATR) pointed at 0.24. The RSI (14) points at 37.70%, while the 14-day stochastic is at 24.10% with the period’s ATR at 0.28. The stock’s 9-day MACD Oscillator is pointing at -0.06 and -0.19 on the 14-day charts.
In the most recent analyst report for Orphazyme A/S (NASDAQ: ORPH), Guggenheim downgraded it to a Sell rating. They previously had a Buy rating on the stock. Analysts offering their rating for ORPH stock have a consensus rating for the stock as Underweight. Currently, 2 brokerage advisors rate ORPH as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is ORPH’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.00 and a high of $2.06, with their median price target at $1.53. Looking at these predictions, the average price target given by analysts is for Orphazyme A/S (ORPH) stock is $1.53.